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Abstract
Background: Preterm birth and very small size at birth have long-term effects on neurodevelopment and growth.
A relatively small percentage of extremely low birthweight babies suffer from severe neurological disability;
however, up to 50 % experience some neurodevelopmental or learning disability in childhood. Current international
consensus is that increased protein intake in the neonatal period improves both neurodevelopment and growth,
but the quantum of protein required is not known. This trial aims to assess whether providing an extra 1 to
2 g.kg-1.d-1 protein in the first 5 days after birth will improve neurodevelopmental outcomes and growth in
extremely low birthweight babies.
Methods/Design: The ProVIDe study is a multicentre, two-arm, double-blind, parallel, randomised, controlled trial. In
addition to standard intravenous nutrition, 430 babies with a birthweight of less than 1000 g who have an umbilical
arterial line in situ will be randomised in 1:1 ratio to receive either an amino acid solution (TrophAmine®) or
placebo (saline) administered through the umbilical arterial catheter for the first 5 days. Exclusion criteria are
admission to neonatal intensive care more than 24 h after birth; multiple births of more than 2 babies; known
chromosomal or genetic abnormality, or congenital disorder affecting growth; inborn error of metabolism, and
in danger of imminent death.
Primary outcome: Survival free from neurodevelopmental disability at 2 years’ corrected age, where
neurodevelopmental disability is defined as cerebral palsy, blindness, deafness, developmental delay
(standardised score more than 1 SD below the mean on the cognitive, language or motor subscales of the
Bayley Scales of Infant Development Edition 3), or Gross Motor Function Classification System score ≥1.
Secondary outcomes: Growth, from birth to 36 weeks’ corrected gestational age, at neonatal intensive care
discharge and at 2 years’ corrected age; body composition at 36 to 42 weeks’ corrected postmenstrual age and
at 2 years’ corrected age; neonatal morbidity, including length of stay; nutritional intake.
Discussion: This trial will provide the first direct evidence of the effects of giving preterm babies a higher intake
of intravenous protein in the first week after birth on neurodevelopmental outcomes at 2 years corrected age.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12612001084875.
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Background
Advances in neonatal intensive care mean that the ma-
jority of preterm babies, even at the extremes of gesta-
tion, now survive infancy, childhood and adolescence
[1]. The ultimate goal for neonatal care is optimal
growth, neurodevelopment and long-term health for
survivors [2]. A relatively small percentage of preterm
babies suffer from severe neurological impairment;
however, up to 50 % of extremely low birthweight
(ELBW; birthweight <1000 g) babies experience some
neurodevelopmental or learning impairment in child-
hood [3]. Current international consensus is that in-
creased protein intake in the neonatal period improves
neurodevelopment, growth, and body composition, but
the quantum of protein required is not known. There-
fore, it is now crucial that fundamental elements of
neonatal nutrition care, such as the protein intake re-
quired for optimal growth and how this influences neu-
rodevelopment and long-term health for preterm
babies, are addressed.
The fastest rate of postnatal growth in the human life-
cycle is (potentially) that of a preterm baby between 23
and 27 weeks’ gestation when weight gain is approxi-
mately 21 g.kg-1.d-1 [4]. However, faltering growth at the
equivalent gestational age is common in preterm babies
[5, 6], due to the difficulties in providing nutrition suffi-
cient to support this rate of growth [6, 7]. Preterm ba-
bies frequently suffer both fetal and postnatal growth
restriction leading to a different pattern of postnatal
weight gain and body composition, including lower
length at term-equivalent age, lower lean muscle mass,
and higher total body fat mass [6, 8–10]. Each of these
patterns of growth is associated with an increased risk of
adult disease [11–13] and both fetal growth restriction
and postnatal faltering growth also are associated with
adverse neurodevelopmental outcome [14, 15].
Suboptimal nutrition likely contributes to both the fal-
tering postnatal growth and impaired neurodevelopmental
outcomes that are seen commonly in ELBW babies
[16, 17]. In preterm babies, length and head growth
appear to be affected early, in contrast to the classic
faltering growth of poorly nourished term infants, with
Z-scores falling by 1–2 standard deviations for all mea-
sures of growth during the first month of postnatal life
[18, 19]. This early effect on head growth likely reflects
the extremely rapid brain growth that occurs at the
gestational ages ELBW babies are receiving suboptimal
nutrition, as head circumference correlates with brain
volume [20]. Volumetric magnetic resonance imaging
(MRI) analyses suggest that cerebellar surface area in-
creases 30-fold in the last 16 weeks of pregnancy and
cerebral cortical volume increases four-fold from 28 to
40 weeks’ gestational age [21–23]. This very rapid de-
velopment may also result in greater vulnerability to
damage from less than optimal nutrition. Indeed, in
adolescents born preterm, performance in final school
exams and intelligence quotient (IQ) score are best
predicted by the total volume of white matter in the
brain detected on MRI scans, irrespective of the pres-
ence or severity of other brain abnormalities [24], with
70 % of the variance in IQ explained by total white
matter volume and the cross-sectional area of the corpus
callosum [24].
Thus, a key modifiable factor for improving neurode-
velopmental outcome in preterm babies is improving
growth, especially head growth, by optimising nutritional
intake in the early postnatal period. Retrospective data
suggest that, across a range of protein intakes that were
below international recommendations, each 1 g.kg-1.d-1
increase in protein intake in the first week after birth
in ELBW babies improves Mental Development Index
scores by 8 points on a Bayley II assessment at
18 months [25]. However, not all data are consistent
in this regard [26], few data are from robust rando-
mised controlled trials and even fewer data are from
studies in which protein and other nutrient intakes
met international recommendations.
We previously have reported that babies with a birth-
weight of <1200 g failed to meet consensus recommended
intravenous nutrient intakes [7, 27–29], consistent with
international experience [30, 31], and that this was par-
ticularly common in ELBW babies. Close adherence to
nutritional guidelines designed to increase nutritional in-
takes to match international recommendations does result
in both increased protein intakes and significantly better
growth for weight, length and head circumference, al-
though the benefit for length growth was less than that for
weight and head circumference [18]. However, despite
these improvements, growth rates are still less than intra-
uterine growth velocity at comparable gestational ages, the
currently accepted recommended goal for ELBW babies
[32]. This may be because protein intake in the first week
after birth remains less than estimated placental protein
uptake in utero between 23 and 27 weeks’ gestational age
(3.6 to 4.8 g.kg-1.d-1) [33] and is, therefore, still insufficient
to support in utero protein accretion rates. Indeed, better
linear growth is associated with higher protein intakes in
the first week after birth [19]. We, therefore, hypothesise
that a higher protein intake during the first week after
birth will improve neurodevelopmental outcomes at age
2 years’ corrected age.
In clinical practice, recommended protein intakes are dif-
ficult to achieve due to the low fluid volumes administered
to ELBW babies during the first week after birth and their
need for other infusions containing non-nutritive fluids
such as drugs. We propose to utilise the umbilical artery
catheter (UAC) to deliver additional protein, substituting
the non-nutritive fluids usually given via the UAC with an
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amino acid solution. This research will fill an urgent need
for data from randomised controlled trials investigating the
effect of early nutritional practices on clinically important
outcomes in these most vulnerable babies.
Hypothesis
The primary hypothesis is that for ELBW babies, an
extra 1 g.d-1 of protein in the first 5 days after birth will
improve survival free from any neurodevelopmental dis-
ability at 2 years’ corrected age. The secondary hypoth-
eses are that increased protein intake in the first week
after birth has benefits relating to neonatal morbidity,
length of neonatal intensive care unit (NICU) stay,
growth and body composition.
Aims and objectives of this trial
We propose replacing the non-nutritional fluids (saline)
that currently are administered via the UAC with an
intravenous amino acid solution and will assess the ef-
fect of this intervention through a randomised, placebo
controlled trial. The aim is to determine whether an
additional 1 to 2 g.kg-1.d-1 protein (amino acid solution)
via the UAC starting within 24 h of birth and continued
for 5 days will (i) improve survival free of neurodisability
at age 2 years’ corrected; (ii) improve body composition,
and (iii) prevent faltering growth at NICU discharge.
Specific aims are to determine the effect of the inter-
vention on:
 Survival free of neurodisability at 2 years’ corrected age
 Growth, from birth to 36 weeks’ postmenstrual age,
at NICU discharge and at 2 years’ corrected age.
 Body composition, at 36 weeks’ postmenstrual age
measured by air displacement plethysmography, and
at 2 years’ corrected age




Multicentre, double-blind, two-arm, parallel, randomised,
controlled trial.
Ethical approval
The Northern B Health and Disability Ethics Committee
has given ethical approval for this study (No 13/NTB/84),
and each participating site has institutional approval
through local institutional review processes. The New
Zealand National Screening Unit has given approval for
access to the Newborn Metabolic Screening data.
Inclusion criteria
Babies with a birthweight of less than 1000 g who have a
UAC in situ in an acceptable position.
Exclusion criteria
Babies admitted to neonatal intensive care more than
24 h after birth; multiple births of more than 2 babies;
known chromosomal or genetic abnormality, or con-
genital disorder affecting growth; inborn error of metab-
olism; in danger of imminent death.
Trial entry and randomisation
Parents will be given a written information sheet about
the study antenatally (where possible), which will be
reviewed with them by a member of the study team. If
birth occurs without time for this to happen, informa-
tion will be given to the parents as soon as is feasible
after birth and reviewed with them by a member of the
study team. Within 24 h of birth and once a UAC has
been placed, eligible babies will be randomised to either
the placebo group or the intervention group. Babies for
whom it was not possible to obtain consent antenatally
will be enrolled based on a waiver of consent (approved
by the ethics committee) with a requirement that in-
formed, written consent is obtained within 24 h. If con-
sent is not obtained within 24 h of randomisation, the
baby will be withdrawn from the study.
Study groups and management
Babies in the placebo group will receive 0.45 % saline
through the UAC (standard therapy). Babies in the inter-
vention group will receive an amino acid solution (8.5 %
TrophAmine®, B Braun Medical, Irvine, USA) through
the UAC giving an extra 1 g.d-1 of protein above stand-
ard intravenous nutrition. Babies in both groups will re-
ceive routine neonatal care including intravenous and
enteral nutrition according to each centre’s practice.
Randomisation
Within 24 h of birth and once a UAC has been placed
in an acceptable position, babies will be enrolled by
medical and research staff and randomly allocated in a
1:1 ratio to treatment and placebo groups via a web-based
interface maintained and concealed by an independent
database controller. Twins will be randomised as separate
babies. Randomisation will be stratified for recruitment
centre (each centre has different nutrition practices), sex
and appropriate-for-gestational-age/small-for-gestational-
age status (these variables influence growth and body
composition), using blocked randomisation with variable
block sizes.
Blinding
Subjects and their families, clinical staff, investigators
and assessors at follow up appointments will be blinded
to treatment allocation throughout the entire study.
Intervention and placebo fluids will be made by an inde-
pendent contractor and will be identical in appearance
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and identified only by a randomly generated numerical
identifier. Composition of the fluid in each bag will be
known only by the independent database controller.
Unblinding should occur only in exceptional circum-
stances when knowledge of the actual treatment is abso-
lutely essential for further management of the patient. If
unbinding is deemed to be necessary by a neonatologist,
the neonatologist is encouraged to discuss this with the
overall responsible investigator (FHB). The actual alloca-
tion will not be disclosed to parents and/or other study
personnel. Any code break that occurs will be reported
to the principal investigator and Steering Group without
identifying treatment allocation.
Intervention
All babies will receive nutrition according to individual
neonatal intensive care unit practices. In addition, babies
will be randomised to one of two groups:
Treatment group: Babies will receive an infusion of
8.5 % TrophAmine® at 0.5 ml.h−1 via the UAC, providing
1 g protein in 12 ml or 1–2 g.kg−1.d−1 additional protein,
depending on birthweight. Placebo group: Babies will
receive an infusion of 0.45 % saline at 0.5 ml.h−1 via a
UAC (current standard practice). Both solutions will
contain heparin 0.5 iU.ml-1. The intervention will con-
tinue for 120 h.
Blood sample analysis
Routine biochemical monitoring will take place in ac-
cordance with local guidelines. Concentrations of po-
tassium, pH, bicarbonate, base excess and lactate will
be recorded daily. In addition, blood samples will be
collected on day 1 (24 h after UAC infusion starts) and
day 5 (after the UAC study fluids cease) for the meas-
urement of serum concentrations of urea, albumin,
total protein, globulin, calcium and phosphate concen-
trations on days 1 and 5, and ammonia concentration
on day 5. Study blood results will not be revealed to
attending physicians.
Newborn metabolic screening
Blood spots taken for routine Newborn Metabolic
Screening will be taken immediately before and after the
5-day intervention period. Consent has been granted by
the New Zealand National Screening Unit for access to
the Newborn Metabolic Screening data, including amino
acid and acyl carnitine concentrations.
Monitoring of nutritional intake
Total enteral and intravenous intakes will be recorded
daily until day 28. Mean daily protein, energy and other
nutrient intakes will be calculated based on actual intakes.
Full enteral feeds will be defined as the day when no fur-
ther intravenous nutrition is given or 150 ml.kg-1d-1
enteral feeds is reached. Energy and protein intakes will
be calculated using preterm transitional breast-milk
composition for the first 2 weeks (65 kcal and 1.5 g
protein.100 ml−1) and mature breastmilk composition
thereafter (72 kcal and 1.2 g protein.100 ml−1) [34–38].
Participant withdrawal
Development of significant renal impairment (serum
creatinine > 130 μmol.l−1) or diagnosis of an inborn error
of metabolism requiring prescribed protein intakes will
result in the intervention being discontinued. Partici-
pants will be withdrawn from the trial at parental re-
quest or if the attending physician determines that this
is essential for the baby’s care. Consent will be re-




The primary outcome will be survival free from any
neurodevelopmental disability at 2 years’ corrected age.
Assessment will include the Bayley Scales of Infant De-
velopment Edition 3 (Bayley III), neurodevelopment,
growth and body composition. Cerebral palsy (loss of
motor function and abnormalities of muscle tone and
power) and other impairment outcomes will be assessed
according to previously reported criteria [39]. The severity
of gross motor function will be classified using the Gross
Motor Function Classification System [40]. Children with
severe developmental delay who are unable to complete
the psychological assessment will be given a standardised
score of - 4 SD. Children will be considered blind if visual
acuity in both eyes is worse than 6/60 and deaf if their
hearing loss is sufficient to require hearing aid(s), or
worse.
Children will be considered to have a neurodevelop-
mental disability if they have cerebral palsy, a gross
motor classification score ≥1 [40], blindness, deafness
or developmental delay, defined as a standardised score
for cognitive, motor or language scales more than 1 SD
below the mean [41]. The neurodevelopmental disabilities
imposed by the various neurodevelopmental impairments
will be classified as severe, moderate or mild [39].
Secondary outcomes
Growth Weight, length and head circumference will be
measured at birth, 28 days, 8 and 36 weeks’ postmenstrual
age, and at discharge. Weight, height and head circumfer-
ence will be measured at 2 years’ corrected age. All mea-
surements will be by trained staff using validated,
repeatable methods [42, 43]. All growth data Z-scores will
be calculated individually for each baby using appropriate
normative data. Growth velocity (GV) will be calculated
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using: GV = [1000 × ln(Wn/W1)]/(Dn ‐D1) where W=
weight (g) and D = day after birth on days n (end of time
interval) and 1 (beginning of time interval) [44].
Body composition Body composition, where possible,
will be measured by air displacement plethysmography
at 36 to 42 weeks’ post-menstrual age and at 2 years’
corrected age.
Neonatal outcomes The presence of morbidities at
36 weeks’ post-menstrual age, including intraventricular
haemorrhage (IVH), severe IVH (Grade 3 or 4 defined
using the grading system from Papile et al. [45]), peri-
ventricular leukomalacia, chronic lung disease (need for
oxygen at 36 weeks’ post-menstrual age or 28 days after
birth if born after 32 weeks’ gestation), retinopathy of
prematurity grades 3 and 4 as per the International Clas-
sification of Retinopathy of Prematurity [46], necrotising
enterocolitis (defined as Bell’s stage 2 or higher [47]), pa-
tent ductus arteriosus diagnosed by echocardiography
needing treatment, length of NICU stay and late-onset
sepsis (beyond 7 days after birth and defined as a posi-
tive bacterial culture in cerebrospinal fluid, urine or
blood with clinical signs of infection and with antibiotics
for 5 or more days with the intention of treating an in-
fection, or treatment for a shorter period if the patient
died. If after 10 days of appropriate antibiotic therapy
there was demonstration of sterile culture and then the
same organism was cultured or if a different organism
was cultured from a subsequent culture, this will be con-
sidered an additional episode).
Nutritional intake Intravenous and enteral nutritional
intake until 28 days (fluid, energy, protein, fat, carbohy-
drate, vitamins and minerals). Feed type and nutritional
supplementation at NICU discharge.
Statistical considerations
Sample size A total of 430 babies (n = 215 in each
group) will provide 85 % power at a 5 % level of signifi-
cance (two-sided), to detect an absolute difference of
15 % in survival free of disability between the two
groups at 2 years’ corrected age. The sample size has
taken into account a 10 % loss to follow up rate and a
disability rate in the control group of 50 %.
Statistical analyses Statistical analyses will be per-
formed on an intention-to-treat basis. Missing outcome
data will not be imputed in the primary analysis, as the
key assumption of missing at random is not likely to
hold in the analysis population. Sensitivity analyses will
be conducted, however, using multiple imputations
method to explore the potential impact of missing data
on outcomes. The characteristics of those participants
with missing data will be compared between two treat-
ment groups. Per protocol analysis will be performed for
those who received at least 80 % of the intended treat-
ment. Sub-group analysis will be conducted on the treat-
ment outcomes in relation to total protein received and
to the extra study dose received. Statistical tests will be
two-sided at a 5 % significance level. Twins will be ran-
domised as separate babies, with the non-independence
of these pairs taken into account during analysis.
Baseline characteristics of all randomised babies and
their mothers will be summarised for each group as well
as overall using descriptive statistics. Continuous vari-
ables will be reported as numbers of observed and miss-
ing values, mean, standard deviation, median and range.
Categorical variables will be described as frequencies
and percentages. The primary outcome, survival free of
disability, will be first presented as unadjusted relative
risk (RR) with 95 % confidence interval (CI). Generalised
linear regression models appropriate to continuous and
categorical outcomes will be used to evaluate the treat-
ment difference between two groups, adjusting for
stratification variables and other baseline confounders
that are closely associated with the outcomes (e.g. birth
weight, sex and treatment with antenatal steroids). Ad-
justed RRs and 95 % CIs will be estimated using a log
link. Analyses of growth outcomes will be performed
following completion of NICU discharge assessments
but will not be revealed to assessors of the Bayley III at
2 years’ corrected age.
Data monitoring and other quality control measures
A Trial Steering Committee has been formed to monitor
the conduct of the study. The terms of reference were
agreed at the first meeting (before the trial began). Trial
procedures will be in accordance with the CONSORT
guidelines [48, 49]. The Trial Steering Committee is respon-
sible for advising investigators regarding trial continuation
or cessation should issues of futility or safety arise, and
meet within a month of all Data Monitoring Committee
meetings to consider their recommendations.
The terms of reference for an independent Data Moni-
toring Committee were agreed at the first meeting. An
independent Safety Monitoring Committee has also been
formed. During the period of recruitment, aggregated
summaries of death or other serious adverse event that
the local investigator believes should be referred will be
supplied, in strict confidence, to the Safety Monitoring
Committee. The Safety Monitoring Committee will re-
view individual reports of adverse events. Group alloca-
tion will not be revealed to the Safety Monitoring
Committee or the investigators. Should the Safety
Monitoring Committee rule that the intervention may
have impacted on the adverse outcome, this will be
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immediately reported to the chair of the Trial Steering
Committee. The Steering Committee will decide on the
actions to be taken.
Discussion
This multicentre randomised controlled clinical trial aims
to assess whether a higher protein intake in the first 5 days
after birth will improve survival free of disability in ex-
tremely low birthweight babies. Until data from large,
well-designed randomised trials are available to assess the
effects of earlier higher intravenous protein intakes it is
difficult to develop meaningful, evidence-based nutrition
guidelines. A conclusive outcome will provide important,
reliable evidence of great relevance for the nutritional
management all preterm babies <1000 g at birth in set-
tings where intensive care and intravenous nutrition are
provided, because it involves administering additional pro-
tein through the simple substitution of one fluid for an-
other using an existing commercial amino acid solution.
This intervention has the potential to improve signifi-
cantly both short and long-term health outcomes for pre-
term babies and, therefore, to reduce health costs for
these children as they reach adolescence and adulthood. If
successful this simple, readily available and low cost inter-
vention is likely to result in a rapid change in international
practice, benefiting preterm babies worldwide.
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